CompletedNot Applicable

Clinical Validation of AI-Assisted Radiotherapy Contouring Software for Thoracic Organs at Risk

China500 participantsStarted 2022-09-30

Plain-language summary

The goal of this clinical trial is to evaluate performance and clinical applicability of AI-assisted radiotherapy contouring software (iCurveE) for thoracic organs at risk. The main question it aims to answer is: • Does AI-assisted contouring (AI contouring with manual modification) offer greater accuracy and time efficiency compared to manual contouring? After screening, the qualified participants' thoracic CT images will be anonymized and segmented using three methods: manual, AI (AI-only), and AI-assisted contouring. The researchers will compare the results generated by the three different contouring methods with the ground truth established by expert consensus, in order to evaluate both accuracy and time-related parameters

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. ≥18 years old, no gender limit.
✓. Patients diagnosed with breast cancer, lung cancer, or esophageal cancer, who are scheduled for chest CT scanning followed by thoracic radiotherapy.
✓. CT slice thickness ≤5mm.
✓. Patients understand the goal of the trial, are willing to attend the trial and sign the informed consent.

Exclusion criteria

✕. Congenital malformations or abnormal anatomical structures resulting from non-tumor factors in the scan area.
✕. Artifact, prosthesis or implantation causing images undistinguishable.
✕. CT images not conforming to DICOM standards.
✕. Investigators consider not suitable.

What they're measuring

volumetric DICE similarity coefficient, vDSC

Timeframe: Within 6 months after enrollment

Contouring time (min)

Timeframe: Within 6 months after enrollment

Trial details

NCT IDNCT05787522

SponsorTianjin Medical University Cancer Institute and Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-27

View on ClinicalTrials.gov More Lung Cancer trials